Does This Biotech Have the Secret to Conquering Covid Variants?
Gritstone Bio (NASDAQ: GRTS) is far from being the first to the coronavirus vaccine finish line. The biotech company's vaccine candidate just began phase 1 trials this year. Gritstone's clinical trials are in the earliest stage.